交易 Lyell Immunopharma Inc - LYEL 差价合约

交易条件

• 类型该金融市场可进行差价合约交易。了解更多:差价合约: 差价合约
• 点差: 0.29
• 长仓隔夜仓息调整长仓隔夜仓息调整保证金。您的投资$1,000.00隔夜仓息来自头寸全值的费用-0.02246 %(-$1.12)使用杠杆的交易规模（大约值）$5,000.00来自杠杆的资金 - 美元（大约值）$4,000.00前往平台: -0.02246%
• 短仓隔夜仓息调整短仓隔夜仓息调整保证金。您的投资$1,000.00隔夜仓息来自头寸全值的费用0.00023 %($0.01)使用杠杆的交易规模（大约值）$5,000.00来自杠杆的资金 - 美元（大约值）$4,000.00前往平台: 0.00023%
• 隔夜调整仓息时间: 22:00 (UTC)
• 货币: USD
• 最低成交量: 1
• 保证金: 20.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价保证止损 (GSL) 费用仅在 GSL 被触发时收取。更多详情请参阅我们网站的“服务费用”页面。: 1%

• 保证金。您的投资: $1,000.00
• 隔夜仓息来自头寸全值的费用: -0.02246 %
  (-$1.12)

• 保证金。您的投资: $1,000.00
• 隔夜仓息来自头寸全值的费用: 0.00023 %
  ($0.01)

主要统计数据

• 前收盘价: N/A
• 开仓: 15.06
• 1 年变化: 88.25%
• 日区间: 13.74 - 15.99

交易 Lyell Immunopharma Inc - LYEL

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.